RxDoctor Payments Data

Tess Chamakkala, DO

Internal Medicine · Bethlehem, PANPI 1326530668

Payments from drug & device makers

$6,806in general payments, 2019–2025

Across 329 payments — averaging $20.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$698
  • Corcept Therapeutics$607
  • Cequr Corporation$469
  • Novartis$425
  • Mannkind Corporation$411
  • Novo Nordisk$359
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$6,71099%
  • Education$961%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,806 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$48,429
Medicare patients
113
Services billed
943

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide146$176,849
MounjaroTirzepatide130$155,098
JardianceEmpagliflozin63$69,716
FarxigaDapagliflozin Propanediol21$21,660
TradjentaLinagliptin18$19,156
Tresiba Flextouch U-200Insulin Degludec18$18,056
TrulicityDulaglutide18$16,341
Lyumjev Kwikpen U-100Insulin Lispro-Aabc19$9,179
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$7,073
Lantus SolostarInsulin Glargine,hum.Rec.Anlog54$6,662
Humalog Kwikpen U-100Insulin Lispro25$5,005
Icosapent Ethyl24$4,965
Novolog FlexpenInsulin Aspart19$4,237
Nano 2nd Gen Pen NeedlePen Needle, Diabetic32$3,537
HumalogInsulin Lispro12$3,408

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$359$176,849146 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$698$174,848160 claims
Boehringer IngelheimJardiance, Tradjenta$36$88,87281 claims
AstraZenecaFarxiga$63$21,66021 claims
AbbVieSynthroid$33$3,09235 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$66$1,109109 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Bethlehem

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →